Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12248178 | 0.73 | ADRA2A (0.46) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL31003156 | 0.73 | ADRA2A (0.46) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL282797 | 0.73 | HTR2A (0.43) | ADRA2AADRA1ACYP2D6CA12CA1 | |
| SCHEMBL6376525 | 0.73 | MTNR1A (0.42) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL848282 | 0.73 | KDM4E (0.49) | CYP2D6MEN1KMT2AHTTGAA | |
| SCHEMBL18287881 | 0.71 | ADRA1A (0.68) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL2096168 | 0.71 | CA12 (0.56) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL19122644 | 0.69 | PDE3B (0.40) | ADRA1AMEN1KMT2ACA12CA1 | |
| SCHEMBL19121828 | 0.69 | ACHE (0.39) | ADRA1AMEN1KMT2ACA12CA1 | |
| SCHEMBL6825547 | 0.69 | ADRA2A (0.42) | ADRA2AADRA1ACYP2D6MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689383-B1 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2428516-A1 | Novel phosphorus-containing thyromimetics | Metabasis Therapeutics, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7829552-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2009-05-07 | — | — | US | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1891080-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128055-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | PYGL, THRA, THOP1 | ADRA2A 3338/4885ADRA1A 2767/4885CYP2D6 1066/4885 |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | PYGL, THRA, THOP1 | ADRA2A 3338/4885ADRA1A 2767/4885CYP2D6 1066/4885 |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | THRA, PYGL, THRB | ADRA2A 2843/4885ADRA1A 2045/4885CYP2D6 1634/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | ADRA2A 3672/4885ADRA1A 2915/4885CYP2D6 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.